

JCVI short statement on

Herpes zoster vaccines

JCVI reviewed medical, epidemiological, and economic evidence as well as vaccine safety and efficacy data relevant to a herpes zoster (shingles) vaccination programme. Based on the evidence, the committee recommended that a universal herpes zoster vaccination programme for adults aged 70 up to and including 79 years should be introduced provided that a licensed vaccine is available at a cost effective price. The age range was influenced by data on the burden of disease and the cost-effectiveness of, and the duration of protection conferred by, vaccination. JCVI will issue a full statement in due course. As with all JCVI recommendations, this recommendation will be kept under review.